Lysosomal P-gp targeted agent 1
Lysosomal P-gp targeted agent 1 (Compound 14) is an anti-tumor agent targeting lysosomal P-glycoprotein (Pgp). Lysosomal P-gp targeted agent 1 is selectively transported into lysosomes by overexpressed Pgp, release nitric oxide (NO) to generate reactive oxygen species (ROS), resulting in lysosomal membrane permeabilization (LMP) and inducing apoptosis. Lysosomal P-gp targeted agent 1 can overcome P-glycoprotein-mediated drug resistance and lead to cell cycle arrest, but relatively low toxicity to normal cells. Lysosomal P-gp targeted agent 1 has antitumor activity, significantly inhibits tumor volume.
For research use only. We do not sell to patients.
- CAS No.: 3043797-88-9
- Formula: C39H34N2O9S
- Molecular Weight:706.76
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
In Vitro
Lysosomal P-gp targeted agent 1 (48h) has potent anti-Multidrug resistance (MDR) activity against MCF-7/ADR and A549/Taxol cells, exhibits potent antitumor activity against MCF-7/ADR (IC50 = 0.024 μM) and PC-3 cells (IC50 = 3.36 μM), and inhibitory activity and cytotoxicity against drug-resistant A549/Taxol cells (IC50 = 1.43 μM), exhibited toxicity against HepG2 cells (IC50 = 6.57 μM), weak inhibitory activity against MCF-7 cells (IC50 = 21.20 μM) and weak antitumor activity against A549 cells (IC50 =23.75 μM), displays low cytotoxicity to MCF10A (IC50 = 14.32 μM) and BEAS-2B (IC50 = 14.80 μM) cells[1].
Lysosomal P-gp targeted agent 1 (100 μM) produces higher levels of NO in MCF-7/ADR than in MCF-7 cells, the amounts of NO released intracellularly were associated with their antitumor activity[1].
Lysosomal P-gp targeted agent 1 (100 nM in MCF-7/ADR, 5 μM in A549/Taxol; 1 h or 3 h ) can be selectively pumped into the lysosomes by overexpressed-Pgp and released NO in a time-dependent manner[1].
Lysosomal P-gp targeted agent 1 (25 nM, 50 nM, 100 nM in MCF-7 and MCF-7/ADR, 1 μM, 2 μM, 4 μM in A549, A549/Taxol ; 24 h) serves as a Pgp substrate but not regulated Pgp expression[1].
Lysosomal P-gp targeted agent 1 (25-50 nM) up-regulates the expression of the pro-apoptotic protein Bax and down-regulates the expression of the anti-apoptotic protein Bcl-2 in a concentration-dependent manner, induces the cleavage of PARP1, and up-regulates the expression of caspase-3 and the ratio of PARP1/Cleaved-PARP1, induces apoptosis in MCF-7/ADR cells[1].
Lysosomal P-gp targeted agent 1 (10-50 nM; 24 h) make the total population of apoptotic cells increased from 8.6 to 65.9% in a dose-dependent manner[1].
Lysosomal P-gp targeted agent 1 (10-50 nM; 12d) reduces colony growth at 40 and 50 nM, demonstrating their long-term efffcacy against MCF-7/ADR cells[1].
Lysosomal P-gp targeted agent 1 (20-40 nM; 24 h) interferes with DNA formation and lead to cell cycle arrest[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7/ADR
-
Concentration:10, 25, 50 nM
-
Incubation Time:24 h
-
Result:Population of apoptotic cells increased from 8.6 to 65.9% in a dose-dependent manner.
Up-regulated the expression of the pro-apoptotic protein Bax and down-regulated the expression of the anti-apoptotic protein Bcl-2 in a concentration-dependent manner.
Induced the cleavage of PARP1, and up-regulated the expression of caspase-3 and the ratio of PARP1/Cleaved-PARP1.
-
Cell Line:MCF-7/ADR
-
Concentration:10, 20, 40, 50 nM
-
Incubation Time:12 d
-
Result:Significantly reduced colony growth at 40 and 50 nM, demonstrated their long-term efficacy against MCF-7/ADR cells.
-
Cell Line:MCF-7/ADR
-
Concentration:20, 30, 40 nM
-
Incubation Time:24 h
-
Result:The number of cells in the G2/M phase changed from 11.2 to 18.1, 20.3, and 25.3% in dose-dependent manner.
-
Cell Line:MCF-7, MCF-7/ADR, A549, A549/Taxol
-
Concentration:25 nM, 50 nM, 100 nM in MCF-7 and MCF-7/ADR, 1 μM, 2 μM, 4 μM in A549, A549/Taxol
-
Incubation Time:24 h
-
Result:Served as a Pgp substrate but not regulated Pgp expression.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice (weighing 18-20 g, 4-5 weeks) (established xenograft model using human MDR cell line A549/Taxol)[1]
-
Dosage:1.25, 2.5, 5 mg/kg
-
Administration:Intraperitoneal injection (i.p.), Once every 4 days for 21 days
-
Result:Had antitumor activity, significantly inhibited tumor volume (62.7% decrease at 5 mg/kg)
Observed numerous cellular destruction and decreased Ki67 expression in a dose-dependent manner, suggesting that the tumors were inclined to die or become apoptotic or quiescent.
No substantial histological abnormalities or systemic toxicity were detected in the low-, medium-, and high-dose groups.
Chemical Information
-
CAS No. 3043797-88-9
-
Molecular Weight 706.76
-
Formula C39H34N2O9S
-
SMILES
OC1=CC=C(C=C1OC2=CC=C(C=C2)CCC3=CC=CC(OCCCOC4=NO[N+]([O-])=C4S(=O)(C5=CC=CC=C5)=O)=C3O6)CCC7=CC6=CC=C7
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)